Our objective is to gain a better understanding of the causes of muscle wasting, by determining rates of whole body and muscle protein synthesis and degradation in patients with neuromuscular disease and in normals. The focus will be on myotonic dystrophy, the most prevalent form of muscular dystrophy, and a disorder in which current evidence suggests that muscle wasting is the consequence of decreasing anabolism. The stable isotope L-(1-13C) leucine will be used for study of protein synthesis by a primed-continuous infusion protocol. Muscle protein synthesis rates will be determined by measuring isotope incorporation into muscle biopsy samples. Results from patients with myotonic dystrophy will be compared with studies in normals and in appropriate controls with other neuromuscular diseases. These procedures will permit the calculation of rates of whole body protein synthesis and degradation and validation of studies of muscle protein synthesis. Muscle wasting will be quantitated with muscle mass estimates based on creatinine excretion and total body potassium (40K method). An independent estimate of muscle catabolism will be made by quantitation of 3-methylhistidine excretion. The potential confounding effects of hyperinsulinemia will be obviated by performance of studies on fasted subjects and on subjects in whom insulin secretion is suppressed by continuous somatostatin infusion while insulin, growth hormone, and glucagon are infused. The flux of leucine across skeletal muscle will be studied by the forearm technique during 13C leucine infusion. Blood flow will be measured by both strain gauge plethysmography and dye-dilution techniques. The rate of release of 3-methylhistidine by forearm muscle will be determined in order to estimate the rate of muscle protein breakdown. The possibility that agents affecting rates of muscle protein synthesis may have therapeutic potential in myotonic dystrophy will be explored. Males with myotonic dystrophy are frequently androgen-deficient. Preliminary data indicate that administration of testosterone to males with myotonic dystrophy increases muscle mass as estimated by creatinine excretion and total body potassium. The effect of this hormone on whole body and muscle protein synthesis and on urinary 3-methylhistidine excretion, will be investigated.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS022099-01A1
Application #
3404064
Study Section
Metabolism Study Section (MET)
Project Start
1985-12-05
Project End
1988-11-30
Budget Start
1985-12-05
Budget End
1986-11-30
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Medicine
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Kissel, J T; McDermott, M P; Mendell, J R et al. (2001) Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57:1434-40
Sansone, V; Griggs, R C; Moxley 3rd, R T (2000) Hypothyroidism unmasking proximal myotonic myopathy. Neuromuscul Disord 10:165-72
Orrell, R W; Tawil, R; Forrester, J et al. (1999) Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology 52:1822-6
Kissel, J T (1999) Facioscapulohumeral dystrophy. Semin Neurol 19:35-43
Kissel, J T; McDermott, M P; Natarajan, R et al. (1998) Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 50:1402-6
Tawil, R; McDermott, M P; Pandya, S et al. (1997) A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 48:46-9
(1997) A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. Neurology 48:38-46
Sansone, V; Griggs, R C; Meola, G et al. (1997) Andersen's syndrome: a distinct periodic paralysis. Ann Neurol 42:305-12
Tawil, R; Forrester, J; Griggs, R C et al. (1996) Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol 39:744-8
MOxley 3rd, R T (1996) Proximal myotonic myopathy: mini-review of a recently delineated clinical disorder. Neuromuscul Disord 6:87-93

Showing the most recent 10 out of 36 publications